<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979847</url>
  </required_header>
  <id_info>
    <org_study_id>KoreaUAnamH</org_study_id>
    <nct_id>NCT02979847</nct_id>
  </id_info>
  <brief_title>Hybrid Catheter Ablation for Persistent Atrial Fibrillation</brief_title>
  <official_title>Epicardial Catheter Ablation in Repeated Procedure for Persistent Atrial Fibrillation: Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea University Anam Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      prospective randomized controlled trial

      In repeat procedure for persistent atrial fibrillation, Hybrid group (Epicardial ablation +
      Endocardial ablation) versus control group (conventional Endocardial ablation)

      Freedom from AF/Atrial tachycardia and safety
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epicardial (EPI) catheter approach is considered as an accessory to endocardial (ENDO)
      ablation for persistent atrial fibrillation (PeAF). We evaluated the effectiveness and safety
      of EPI ablation as first option to the patients who had previous endocardial ablation for
      PeAF.

      This is prospective randomized controlled, single center study. study population is recurred
      AF patient with failed previous ENDO catheter ablation for PeAF. The investigators randomized
      study population to both groups: Hybrid group (EpI + ENDO ablation) versus control group
      (conventional ENDO ablation). Clinical outcome (Freedom from AF/Atrial tachycardia) and
      procedural safety will be compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from AF/AT recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from sustained AF/AT recurrence without using anti-arrhythmic drug Sustained AF/AT: sustained more than 30 sec documentation in clinical electrocardiography, Holter, event recorder</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Procedure related complication requiring surgical manage, transfusion, medical treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Predictor for recurrence of AF/AT</measure>
    <time_frame>12 months</time_frame>
    <description>To evaluate predictor for recurrence of atrial tachyarrhythmia after repeated catheter ablation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Hybrid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hybrid catheter ablation (both epicardial and endocardial mapping and ablation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>conventional mapping and ablation in endocardial side</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hybrid catheter ablation</intervention_name>
    <description>trans-xyphoid epicardial puncture is performed and 20-pole catheter via SL-1 sheath is inserted. Voltage mapping or activation mapping or CFAE mapping is performed as rhythm status. Epicardial and Endocardial side ablation were performed.</description>
    <arm_group_label>Hybrid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional endocardial ablation</intervention_name>
    <description>trans-femoral puncture is performed. Voltage mapping or activation mapping or CFAE mapping is performed as rhythm status. Endocardial side ablation were performed and Epicardial side is not assessed.</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with persistent AF (AF episode lasting &gt; 7 days)

          -  Patients with symptomatic AF that is refractory to at least one antiarrhythmic
             medication

          -  Patients with recurrent arrhythmia after prior catheter ablation

          -  Patients undergoing a repeat ablation procedure for AF

          -  At least one episode of AF must have been documented by ECG, Holter, loop recorder,
             telemetry, trans telephonic monitoring (TTM), or implantable device within last 2
             years of enrollment in this investigation

          -  Patients must be able and willing to provide written informed consent to participate
             in this investigation

        Exclusion Criteria:

          -  Patients with permanent AF;

          -  Permanent AF will be defined as a sustained episode lasting more than 1 years and
             sinus rhythm never be observed .

          -  Patients for whom cardioversion or sinus rhythm will never be attempted/pursued;

          -  Patients with AF felt to be secondary to an obvious reversible cause

          -  Patients with contraindications to systemic anticoagulation with heparin or warfarin
             or a direct thrombin inhibitor;

          -  Patients with left atrial size â‰¥ 60 mm (2D echocardiography, parasternal long axis
             view)

          -  Moderate to severe valvular disease

          -  Reduced left ventricular function (ejection fraction &lt;40%)

          -  Patients who are pregnant. Pregnancy will be assessed by patients informing the
             physicians.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Hoon Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seung-Young Roh, MD</last_name>
    <phone>+82-10-3612-6876</phone>
    <email>rsy008@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kwang No Lee, MD</last_name>
    <phone>+82-10-9286-1123</phone>
    <email>knlee81@naver.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Korea University Medical Center Anam hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Hoon Kim, President</last_name>
      <phone>+82-2-920-5445</phone>
      <email>yhkmd@unitel.co.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <results_reference>
    <citation>Eckstein J, Zeemering S, Linz D, Maesen B, Verheule S, van Hunnik A, Crijns H, Allessie MA, Schotten U. Transmural conduction is the predominant mechanism of breakthrough during atrial fibrillation: evidence from simultaneous endo-epicardial high-density activation mapping. Circ Arrhythm Electrophysiol. 2013 Apr;6(2):334-41. doi: 10.1161/CIRCEP.113.000342. Epub 2013 Mar 19.</citation>
    <PMID>23512204</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee G, Kumar S, Teh A, Madry A, Spence S, Larobina M, Goldblatt J, Brown R, Atkinson V, Moten S, Morton JB, Sanders P, Kistler PM, Kalman JM. Epicardial wave mapping in human long-lasting persistent atrial fibrillation: transient rotational circuits, complex wavefronts, and disorganized activity. Eur Heart J. 2014 Jan;35(2):86-97. doi: 10.1093/eurheartj/eht267. Epub 2013 Aug 8.</citation>
    <PMID>23935092</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee G, Spence S, Teh A, Goldblatt J, Larobina M, Atkinson V, Brown R, Morton JB, Sanders P, Kistler PM, Kalman JM. High-density epicardial mapping of the pulmonary vein-left atrial junction in humans: insights into mechanisms of pulmonary vein arrhythmogenesis. Heart Rhythm. 2012 Feb;9(2):258-64. doi: 10.1016/j.hrthm.2011.09.010. Epub 2011 Sep 9.</citation>
    <PMID>21907170</PMID>
  </results_reference>
  <results_reference>
    <citation>Pak HN, Hwang C, Lim HE, Kim JS, Kim YH. Hybrid epicardial and endocardial ablation of persistent or permanent atrial fibrillation: a new approach for difficult cases. J Cardiovasc Electrophysiol. 2007 Sep;18(9):917-23. Epub 2007 Jun 16.</citation>
    <PMID>17573836</PMID>
  </results_reference>
  <results_reference>
    <citation>Verheule S, Tuyls E, Gharaviri A, Hulsmans S, van Hunnik A, Kuiper M, Serroyen J, Zeemering S, Kuijpers NH, Schotten U. Loss of continuity in the thin epicardial layer because of endomysial fibrosis increases the complexity of atrial fibrillatory conduction. Circ Arrhythm Electrophysiol. 2013 Feb;6(1):202-11. doi: 10.1161/CIRCEP.112.975144. Epub 2013 Feb 6.</citation>
    <PMID>23390124</PMID>
  </results_reference>
  <results_reference>
    <citation>Eckstein J, Schotten U. Rotors and breakthroughs as three-dimensional perpetuators of atrial fibrillation. Cardiovasc Res. 2012 Apr 1;94(1):8-9. doi: 10.1093/cvr/cvs093. Epub 2012 Feb 13.</citation>
    <PMID>22331500</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Anam Hospital</investigator_affiliation>
    <investigator_full_name>Young-Hoon Kim</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>persistent atrial fibrillation</keyword>
  <keyword>catheter ablation</keyword>
  <keyword>hybrid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

